Purpose: Various reports found a relationship between lymphocyte-related blood parameters (LRBP), including absolute lymphocyte counts (ALC), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) and prognosis of breast cancer. Most of the studies focused on LRBP pre-treatment. Seldom have studies focused on LRBP during radiotherapy. We intended to perform a retrospective cohort study on the prognostic value of LRBP at the time point of lowest ALC during radiotherapy for breast cancer. Patients and methods: A total of 158 female patients were included in radiotherapy group because of the strict limitation standards of complete routine blood test results at pretreatment and pre-operation, and at least once a week during radiotherapy. Besides 221 patients, including the 158 patients of radiotherapy group, were adopted in pre-treatment group and pre-operation group. Results: ALC and PLR at the time point of lowest ALC during radiotherapy are prognostic predictors of breast cancer, and lower ALC and higher PLR are independent significant predictors of poor DFS. Besides, lower ALC, higher NLR and higher PLR at both pretreatment and pre-operation were found to be independent variables for predicting poor DFS. Conclusion: LRBP at pre-treatment, pre-operation, and during radiotherapy may serve as predictors of outcomes of breast cancer.
Introduction
Breast cancer is the most common cancer in females around the whole world. 1 Traditionally, tumor size, presence of lymph node metastasis, clinical stages, pathology grade, and molecular typing are taken as independent prognostic variables in breast cancer. 2 Nowadays, various studies have shown that different immune states lead to different tumorous outcomes. Increasing evidence suggests that inflammatory factors play an important role in tumor initiation, occurrence, development, recurrence, and metastasis. [3] [4] [5] Lymphocyte-related blood parameters (LRBP), including absolute lymphocyte counts (ALC), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR), representatives of inflammatory factors, can reflect the immune system status. [6] [7] [8] Various reports found a relationship between ALC, NLR, and PLR and prognosis of breast cancer. [6] [7] [8] [9] [10] Most of the studies focused on baseline LRBP. Only a few studies focused on the impact of radiotherapy on LRBP in relation to the prognosis. And in these research, time points of LRBP were specifically selected, for example, the time prior to radiotherapy, after 10 fractions of radiotherapy, and at the end of radiotherapy. However, LRBP were varied in different patients during radiotherapy. It seemed that obtaining LRBP during all of the time points, once a week, during radiotherapy and then finding the most representative one to investigate and analyze was a better choice. As radiotherapy leads to lymphopenia, the lowest lymphocyte count during radiotherapy might better represent immune suppression state caused by radiotherapy than lymphocytes of other time points. Therefore, we performed a retrospective cohort study on the prognostic value for breast cancer of LRBP at the time point of lowest ALC during radiotherapy. At the same time, baseline LRBP (before any treatment) and preoperation (before operation) were also collected and analyzed as a comparison with LRBP during radiotherapy and previous relevant studies.
Materials and Methods Patients
This study was reviewed and approved by the ethics committee of The Fifth Medical Center of Chinese PLA General Hospital. Data and research were anonymous to patients. Patients with breast cancer were retrospectively identified using electronic medical records system at The Fifth Medical Center of Chinese PLA General Hospital between January 2007 and December 2014. Prognosis information was obtained by reviewing the electronic medical records, imageological examination and telephonic follow-up. The last followup date was June 2019.
Inclusion and Exclusion
Inclusion criteria were used to get the study population: 1) diagnosed with invasive ductal carcinoma or invasive lobular carcinoma, with clinical stages among I-III, 2) complete lymphocyte-related blood parameters of baseline, preoperative and radiotherapeutic period, 3) treatment at least with operation and radiotherapy, with or without chemotherapy, 4) negative surgical resection margin status and no residual tumor tissues remaining after operation, 5) the whole treatment completed in our hospital. Exclusion criteria were: patients with 1) incomplete data, 2) clinical stages IV carcinoma, 3) double breast cancer, 4) recurrence or death within 3 months after operation, 5) deaths unrelated to breast cancer, 6) immune dysfunction (such as Human Immunodeficiency Virus infection) or immune hyperfunction (such as autoimmune disease), 7) blood diseases (such as aplastic anemia and leukemia) and 8) other fatal diseases.
Data Collection
Medical records were reviewed in order to find clinical data of patients, including name, age, sex, pathologic results (histologic type, histological grade, tumor size, and lymph node status, hormone receptor status, and Her-2 receptor status), surgery (breast-conserving surgery and mastectomy), chemotherapy (adjuvant and neoadjuvant chemotherapy), adjuvant radiotherapy, targeted therapy (trastuzumab) and blood routine results, including ALC, absolute neutrophil count (ANC), and absolute platelet count (PLT). The results of routine blood tests were chosen at several points: baseline (before any treatment), pre-operation (before operation), during adjuvant radiotherapy (blood routine test at least once a week). ALC nadir during radiotherapy was defined as the lowest one of all recorded ALC measures during the whole radiotherapy period. DFS was the end point and was defined as the time from surgery to first relapse or death. ER (estrogen receptor) and PR (progesterone receptor) were considered positive if there were at least 1% positive tumor cells with nuclear staining. Her-2 (human epidermal growth factor receptor 2) was reported positive as the score of 3+ according to immunohistochemistry or 2+ with gene amplification verified by florescent in situ hybridization. It was considered as Her-2(-) when the score was 2+ and the result of florescent in situ hybridization was unavailable. Breast cancer subtypes were defined as follows: Luminal A (ER+ and/or EP+, Her-2-, Ki67<14%), Luminal B (ER+ and/ or EP+, Her-2-, Ki67≥14%) or (ER+ and/or EP+, Her-2+), Her-2+(ER-, PR-, Her-2+) and TNBC (ER-, PR-, Her-2-). Histopathology results were used to obtain TNM stages according to American Joint Committee on Cancer.
Lymphocyte-Related Blood Parameters (LRBP)
ALC, ANC, and PLT levels were obtained from routine blood tests, and NLR and PLR were calculated. NLR was calculated as the ratio of absolute neutrophil count to absolute lymphocyte count and PLR was calculated as the ratio of absolute platelet count to absolute lymphocyte count. LRBP included ALC, NLR, and PLR. Three different groups of LRBP were collected and analyzed, baseline group, pre-operation group, and radiotherapy group. In radiotherapy group, all routine blood results during radiotherapy period were compared to find the lowest ALC during radiotherapy. For each patient, a routine blood test
Statistical Analyses
Statistical analyses were carried out by using SPSS 25.0. Quantitative variables including ALC, NLR, and PLR of the three groups were compared by Wilcoxon rank sum test. The cutoff value was obtained by receiver operating characteristics (ROC) curve and Youden index (Youden index=-sensitivity+specificity-1). Kaplan-Meier method was used to calculate the survival curves. Log rank test was used to compare DFS between different groups. To evaluate the relationship between lymphocyte-related blood parameters and DFS, Cox proportional hazards models were used to get prognostic factors and corresponding hazard ratios (HRs) with 95% confidence intervals (CIs). All statistical tests were two-sided, and P<0.05 was considered statistically significant.
Results

Patient Characteristics
A total of 221 female patients were included in the present study ( Table 1 ). The median age at the time of diagnosis was 47 years (range 23-73 years). All patients underwent radical mastectomy (51, 23.1%) or breast conserving surgery (170, 76.9%). Chemotherapy drugs included anthracyclines (A), cyclophosphamide (C) and docetaxel (T), and chemotherapy regimens were 4 to 8 courses, every 3 weeks a course, including AC, AT, TC and AC-T. All patients received adjuvant radiotherapy after operation. The radiation dose of postoperative radiotherapy was 50-60 Gy/25-30 fractions (5 days/ week, 5-6 weeks). 171 patients, after breast-conserving surgery, received radiotherapy of 60 Gy (whole breast irradiation 50 Gy + tumor bed boost 10 Gy). In 51 patients, after mastectomy, 11 patients with tumor stage T4 received radiotherapy of 60 Gy (whole breast irradiation 50 Gy + tumor bed boost 10 Gy), while the other 40 patients received radiotherapy of 50 Gy. All 211 patients had complete routine blood result records of baseline and pre-operation, which were all used for analysis, but only 158 patients' routine blood result records during radiotherapy were adopted into research, because for the other 53 patients, there was lack of adequate data during radiotherapy, namely not meeting the standard of routine blood tests, ie, at least once a week during radiotherapy. In 158 patients with lowest ALC during radiotherapy, 122 
Optimal Cutoff Point of LRBPs for DFS
The ROC curve of DFS was used to obtain the optimal cutoff points of ALCs, NLRs, and PLRs. The result was shown in Figures 1-3 and 
Univariate and Multivariate Analyses for DFS
We performed univariate and multivariate analyses for DFS in baseline group, pre-operation group, radiotherapy group and baseline characteristic group (Tables 4 and 5 ). In baseline group, higher ALC, lower NLR, and lower PLR were associated with good prognosis in univariate analysis. Multivariate analyses revealed higher ALC, lower NLR, and lower PLR were independent prognostic factors for improved DFS (respectively: HR(95% CI): 0.43(0.24-0.77), P=0.005; HR Abbreviations: ROC, receiver operating characteristics curve; ALC, absolute lymphocyte counts; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio. Abbreviations: ROC, receiver operating characteristics curve; ALC, absolute lymphocyte counts; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio. Abbreviations: ROC, receiver operating characteristics curve; ALC, absolute lymphocyte counts; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio. Abbreviations: ALC, absolute lymphocyte counts; DFS, disease-free survival. Figure 10 Kaplan-Meier curves of low and high ALC of radiotherapy for DFS. Abbreviations: ALC, absolute lymphocyte counts; DFS, disease-free survival. Abbreviations: NLR, neutrophil-to-lymphocyte ratio; DFS, disease-free survival. Figure 9 Kaplan-Meier curves of low and high PLR of pre-operation for DFS. Abbreviations: PLR, platelet-to-lymphocyte ratio; DFS, disease-free survival.
Discussion
We performed this retrospective cohort study on the prognostic value for breast cancer of LRBP at the time point of lowest ALC during radiotherapy. At the same time, LRBP of baseline and pre-operation were also collected and analyzed as a comparison with LRBP during radiotherapy and previous related studies. Various reports found a relationship between ALC, NLR and PLR and prognosis of breast cancer, most of the studies focusing on LRBP of baseline. [6] [7] [8] [9] [10] However, only a few studies focused on the impact of radiotherapy on LRBP in relation to prognosis. And in these research, time points of LRBP were artificial selection, and most of them were before or after radiotherapy. 11, 12 It seemed that obtaining LRBP of all time points, once a week, during radiotherapy and then finding the most representative one to investigate and analyze was a better choice. As radiotherapy leads to lymphopenia, the lowest lymphocyte count during radiotherapy might better represent immune suppression state caused by radiotherapy than lymphocytes during other time points, so LRBP at the time point of lowest ALC during radiotherapy was chosen in our study, which was different from the previous research. Most similar studies focused on LRBP of one specific point during therapy, for example, before treatment, before operation, on a certain time of chemotherapy or radiotherapy. Our study selected data from three different periods of therapy, including baseline, pre-operation and radiotherapy. Variation of LRBP was seen with the change of treatment methods and treatment time, but we could see the relatively stable predictive function of LRBP for prognostic value in different treatment periods, except for NLR at the time of lowest ALC during radiotherapy.
Moreover, although most patients undergoing radiotherapy were required to have routine blood test once a week to evaluate their physical condition, as a matter of fact, only a few patients received routine blood test once a week, because most of them were outpatients, hard to manage, and compared to chemotherapy with more systemic side effects, the side effects of radiotherapy were mainly local, and systemic reactions were mild. 13 [16] [17] [18] [19] [20] Neutrophils were considered to have a relationship with tumor progression and metastasis by releasing immune mediators, such as interleukin-8, neutrophil elastase, and matrix metalloproteinase-9. [21] [22] [23] Platelets were found to be associated with promoting angiogenesis, releasing adhesion molecules and growth factors, and modifying the extracellular matrix, and therefore having a correlation with progression and metastasis of tumors. [24] [25] [26] Previous studies have shown that both higher NLR and higher PLR have a relationship with poor prognosis in breast cancer, however, the underlying mechanisms are still unclear. It is now thought that higher NLR and higher PLR mean increased neutrophils and platelets and/or decreased lymphocytes, which suggests poor survival in breast cancer. In the radiotherapy group, because the inclusion criteria included routine blood test at least once a week during Figure 12 Kaplan-Meier curves of low and high PLR of radiotherapy for DFS. Abbreviations: PLR, platelet-to-lymphocyte ratio; DFS, disease-free survival. Figure 11 Kaplan-Meier curves of low and high NLR of radiotherapy for DFS. Abbreviations: NLR, neutrophil-to-lymphocyte ratio; DFS, disease-free survival.
radiotherapy, only 158 patients' LRBP were adopted into research. As mentioned previously, it was not easy to find a patient with routine blood test once a week during radiotherapy, so despite the fact that only 158 patients' radiotherapy data were involved in analysis, a small quantity as it may be, it was still very valuable. In multivariate analyses for DFS, higher ALC and lower PLR were found to be independent variables for predicting favorable outcomes (respectively: HR(95% CI): 0.37(0.15-0.89), P=0.027; HR(95% CI): 3.40(1.72-6.72), P<0.001), which meant that ALC and PLR at the time point of lowest ALC during radiotherapy were associated with survival. While, NLR did not show a significant association with patients' DFS both in univariate and multivariate analyses. But in NLR's Kaplan-Meier curves for DFS, two curves represented higher NLR and lower NLR was separate, higher NLR indicated poor DFS. Besides, in univariate and multivariate analyses, hazard ratios with 95% confidence interval of higher NLR were Abbreviations: DFS, disease-free survival; ALC, absolute lymphocyte counts; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; RT, radiation therapy; LRBP, lymphocyte-related blood parameters; HR, hazard ratio; CI, confidence interval. Abbreviations: DFS, disease-free survival; ER, estrogen receptor; PR, progesterone receptor; Her-2, human epidermal growth factor receptor 2; HR, hazard ratio; CI, confidence interval.
1.54(0.72-3.29), and 1.54(0.72-3.29), respectively, both greater than one, meaning the higher the NLR, the worse the outcomes. P-values of NLR for DFS in univariate and multivariate analyses were 0.250 and 0.265, both greater than 0.05, but when considering small sample size, higher NLR may be associated with poor DFS in a large sample analysis. Which, however, was just speculation, and needs to be proven. As lymphocytes were considered to be the most sensitive cells to radiotherapy followed by neutrophils, monocytes, then platelets and erythrocytes, the counts of lymphocytes decreased obviously during the process of radiotherapy, and eventually, among 158 patients of radiotherapy group, at the point of lowest ALC during radiotherapy, 72.2% patients had lymphopenia, however, in 221 patients of baseline and pre-operation groups, only 4.5% and 7.2% patients had lymphopenia, respectively. 27 The mean ALC, NLR, and PLR of radiotherapy group in 158 patients were 0.86±0. This small size, retrospective research had certain inherent limitations. The number of patients were not big, all from one institution, only 221 patients were included in the study, and only 158 patients' LRBP were adopted in analysis in radiotherapy group. However, the reason for the small size was that we strictly limited standards in that patients had to have complete routine blood test results of all time points during treatment, including baseline, pre-operation and radiotherapy period. Further, 63 patients of the 211 were excluded from analysis in the radiotherapy group because they had incomplete routine blood test results, ie, they did not go for a blood test at least once a week during radiotherapy. As mentioned previously, it was not easy to get a record of patients with routine blood tests once a week during radiotherapy. Despite the small number of the study, it has provided unstudied content of the prognostic value for breast cancer of LRBP at the time point of lowest ALC during radiotherapy.
Conclusion
Our study suggests that ALC and PLR at the time point of lowest ALC during radiotherapy are prognostic predictors of breast cancer, and lower ALC and higher PLR are independent significant predictors of poor DFS. Besides, lower ALC, higher NLR and higher PLR at both baseline and pre-operation were found to be independent variables for predicting poor DFS, as shown in previous studies.
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